Dr. David F. Yankelevitz

• 
  www.tobacco.org/articles/org/liggett/ - [Cached Version]
  Last Visited: 5/8/2009  

  Claudia Henschke and David Yankelevitz of Weill Cornell Medical College are key figures in a multicenter study of spiral CT screening for lung cancer and leading proponents of screening. . . .
  ...
  In today's correction, the New England Journal acknowledges that the study's lead authors, Claudia Henschke and David Yankelevitz of Cornell University's Weill Medical College in New York City, received royalties from GE, a big maker of CT scanners, for pending patents on ways to manipulate and interpret CT scans and other medical images. . . .

• 
  www.rt-image.com/content=8804J05C4856928640569A74444090 - [Cached Version]
  Published on: 3/31/2007    Last Visited: 3/31/2007  

  "It's striking how much of an advantage early detection is," says David F. Yankelevitz, MD, I-ELCAP researcher, attending radiologist and professor of radiology and cardio thoracic surgery at Weill Cornell Medical College.

• 
  www.nj.com/news/index.ssf/2007/09/11/ - [Cached Version]
  Published on: 9/11/2007    Last Visited: 9/11/2007  

  David Yankelevitz, a professor of radiology at New York Presbyterian/Weill Cornell Medical Center, called the guidelines "out of step" and expressed his disappointment with the "overall quality" of the academy's review.

• 
  www.healthimaging.com/content/view/8792/89/ - [Cached Version]
  Published on: 11/26/2007    Last Visited: 12/6/2007  

  David Yankelevitz, MD, radiologist at New York-Presbyterian and Weill Cornell Medical College, both located in New York City, spoke about the need to standardize the terminology of the clinical trial.For instance, in the a positive result in the I-ECLAP trial is defined as a nodule 5mm or greater, whereas in the NLST trial, it is considered 4mm or greater.These small differences can produce very different results, he said.
  
  Yankelevitz mentioned the technology drift that occurs while the time of the trial has elapsed, "screening trials are typically quite long, and technology changes rapidly."He said there is a potential for the imaging method to become obsolete before the trial is completed, and it can be difficult to adjust for changes in technology mid-trial.
  
  "Technology can really potentially change results.I don't know where it will be five years from now, ten years from now.Technology is changing just so rapidly," he said.
  
  Yankelevitz also pointed to regimen drifts, which he deemed as analogous to technology drifts because they can affect the trial outcomes.He said that "our understanding of techniques, methods and protocols change amidst trials," which complicates the process.
  
  Both Chiles and Yankelevitz reminded the audience that no radiological method or trial is currently considered the gold-standard in lung cancer detection, but the field still is subject to many years of clinical trials that need to be considered when approaching their patients.

• 
  www.ryalsmeet.com/meetings/NYRS042207/main.htm - [Cached Version]
  Published on: 3/17/2007    Last Visited: 3/17/2007  

  CHEST                                                               David Yankelevitz, Moderator
  ...
  David Yankelevitz

• 
  www.ethicalmarkets.com/?p=446 - [Cached Version]
  Published on: 1/28/2008    Last Visited: 4/2/2008  

  The Center for Science in the Public Interest last week urged six journals that carried articles by Weill Medical College researchers Claudia Henschke and David Yankelevitz to print corrections after confirming reports in The Cancer Letter that the lung cancer researchers failed to disclose patent applications in published articles. . . . An American Heart Association press release urging caution before discontinuing use of Vytorin failed to disclose that the non-profit received $2 million from the Merck/Schering-Plough joint venture that made the drug, the New York Times reported. . . . The investigation by two Congressional committees into the EPA's denial of California's Clean Air Act waiver request has confirmed that EPA staff warned the agency's administrator against denying the waiver.

• 
  www.healthimaging.com/content/view/10219/89/ - [Cached Version]
  Published on: 3/26/2008    Last Visited: 5/22/2008  

  In an email to the NY Times, Henschke and David Yankelevitz, MD, the foundation's secretary-treasurer, wrote, "It seems clear that you are trying to suggest that Cornell was trying to conceal this gift, which is entirely false."

• 
  www.columbiasurgery.org/thoracic/news_thoracic.html - [Cached Version]
  Published on: 6/26/2008    Last Visited: 5/24/2009  

  Dr. Henschke also chaired the Writing Committee of I-ELCAP; the other members were David Yankelevitz, MD, Daniel Libby, MD, Mark Pasmantier, MD, James Smith, MD, and Olli Miettinen, MD, PhD. From the initiation of I-ELCAP, Columbia investigators led by John Austin, MD, have been key collaborators.

• 
  onctalk.com/2007/10/30/lung-cancer-awareness-event-with - [Cached Version]
  Published on: 10/30/2007    Last Visited: 12/10/2007  

  - Dr. David Yankelovitz, one of the lead physicians of the I-ELCAP screening study and radiologist at the Weill Medical College of Cornell University in NYC

• 
  www.tobacco-on-trial.com/2005/06/13/rosen-was-selma-ros - [Cached Version]
  Published on: 1/1/2005    Last Visited: 11/24/2007  

  Cornell Medical College's Dr. David Yankelevitz was asked Monday morning about the nature of Selma Rosen's lung cancer.

Page:  1 2 3 4 5